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Study objective: Accurate perception of airway caliber remains an important issue
in asthma management. The way bronchodilation is perceived is partly related to the
perception of the efficacy of bronchodilators in relieving complaints. In the present
study, we compared the effects of salmeterol, formoterol and placebo on relief of
histamine-induced asthma symptoms and mild bronchusobstruction.
Methods: In this randomized controlled, double blind study, 30 asthmatics were
challenged with histamine until forced expiratory volume in 1 s (FEV1) fell with
X20%. Subjects received salmeterol, formoterol or placebo after the histamine
provocation. Pulmonary function (FEV1) and asthma symptoms (Asthma Symptom
Checklist, Borg Dyspnea Scale) were assessed 5 and 20min later.
Results: FEV1 improved significantly more in the salmeterol and formoterol group
than in the placebo group (Po0:001, Po0:001 and Po0:05, respectively).
Salmeterol and formoterol were not different with regard to the pulmonary
function recovery. No significant differences were found between the effects of
salmeterol, formoterol and placebo on any of the symptom responses at the
different time points.
Conclusions: We conclude that after a histamine-induced mild bronchusobstruction,
a similar asthma symptom recovery occurred when inhaling salmeterol, formoterol
or placebo, despite better recovery of pulmonary function in the active
drug conditions.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
46800; fax: 32 16 346803.
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In asthmatics, a poor correlation has often been
observed between perceived symptoms and pul-
monary function measures, indicating over- or
underperception in many cases.1 Psychological
factors, such as previous asthma experiences and
personality, have been studied to explain the
inconsistent relationship between asthmatic symp-
toms and pulmonary function.2–4 Most often,
blunted perception of bronchusobstruction has
been studied. Misperceiving bronchodilation is,
however, another important aspect, considering
its potential impact on therapeutic compliance
when underperceived and on life-threatening
consequences when overperceived. Few studies
have focused mainly on perception of bronchodila-
tion.5–7
The way bronchodilation is perceived is partly
related to the perception of the efficacy of
bronchodilators in relieving complaints. Short-
and long-acting inhaled b2-agonists play an impor-
tant role in treating bronchusobstruction in asth-
matics. The long-acting b2-agonists, salmeterol and
formoterol, have been shown to be very efficient as
maintenance treatment in asthmatics who, despite
treatment with inhaled glucocorticosteroids, have
persistent noctural asthma and require short-acting
b2-agonists frequently.
8 Formoterol has a rapid
onset of action, compared to salmeterol with a
slow onset of action. Previous study findings have
shown that metacholine-induced severe bronchu-
sobstruction and dyspnea were more rapidly re-
lieved by formoterol and salbutamol than by
salmeterol.9,10
In the present study, we compared the effects of
salmeterol, formoterol and placebo on relief of
histamine-induced asthma symptoms and mild
bronchusobstruction.Methods
Participants
The patients included in this study were between
18 and 60 years old. Patients were referred to the
pulmonary function laboratory to perform a hista-
mine provocation test, in order to confirm their
diagnosis of asthma, in agreement with the GINA
guidelines.11,12 Exclusion criteria were occupa-
tional asthma, non-Dutch speaking, a fall of forced
expiratory volume in 1 s (FEV1) o20% at the end of
the histamine provocation and previous experience
with histamine provocation as this can influenceparticipants’ responses. On the day of the study,
patients had not taken any short-acting b2-agonists
and anticholinergics for 8 h, long-acting b2-agonists
and theophyllines for 24 h and antihistamines and
long-acting anticholinergics for 48 h.
Measures
Asthma symptom measurements Asthma Symptom Checklist (ASC): The ASC is a
36-item questionnaire developed to assess sub-
jective symptomatology in asthmatics.13,14 We
used a Dutch translation, consisting of 6 symp-
tom scales: symptoms of airway obstruction (5
items), dyspnea (3 items), fatigue (6 items),
anxiety (8 items), irritation (6 items), and
symptoms suggestive for hyperventilation (6
items) (7). The Cronbach’s a is 0.93, 0.88,
0.86, 0.87, 0.92 and 0.76, respectively. The
subjects were instructed to indicate on an 11-
point scale, the intensity with which they
experienced a symptom (0 ¼ no symptom,
10 ¼ symptom as bad as possible). Modified 0–10 Borg Dyspnea Scale: A modified
Borg Scale has been proven a valid tool to
measure the degree of dyspnea in patients with
respiratory diseases.15 Patients rated their ‘dif-
ficulty of breathing’ on a modified 0–10 Borg
Scale, going from no difficulty at all (score ¼ 0)
to highly difficult (score ¼ 10).
Pulmonary function measurements
FEV1 was measured by performing forced expira-
tory maneuvers on a Mass-flow Sensor (Sensorme-
dics, Vmax 20C, 2000). Measurements were in
accordance with ERS guidelines.16 FEV1 values are
expressed in liter or % of the predicted value. Two
pulmonary function measurements were performed
at every measure moment; the best of the two
measurements was used for analyses.
Procedure
In this randomized controlled, double blind study,
participants were allocated to one of the three
conditions, depending on the study drug that was
administered at the end of the histamine provoca-
tion: 1/salmeterol, 2/formoterol or 3/placebo.
Pulmonary function and symptoms were assessed
at baseline (measure moment 1), after the hista-
mine provocation (measure moment 2), 5min
(measure moment 3) and 20min (measure moment
4) after the study drug was administered. Every
patient received 400 mg of salbutamol at the end of
the study. To ensure full recovery of the patients,
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assessed a last time 15min after salbutamol was
inhaled (measure moment 5).
The study was performed in the pulmonary
function laboratory of the University Hospital
Gasthuisberg, Leuven (Belgium). Patients came to
the laboratory on a regular weekday to perform a
histamine provocation test. Before the test started,
the researcher (VL) gave standard instructions on
the study and asked oral informed consent. When
the patient was willing to participate, baseline
symptom measurements were assessed, as well as
smoking status and medication intake. Subse-
quently, the technician started the histamine
provocation test according to the Cockroft meth-
od.17 At the end of the provocation, the technician
administered two devices to every subject while
giving standard instructions of bronchodilation:
‘The substances you will be asked to inhale are
bronchodilators. You might well or not know them.
After inhaling them, you may feel that your
symptoms subside. You may feel your airways
opening up. Your chest will loosen up. It will feel
easier to get your breath’. Every patient had to
take first one inhalation of a white turbohaler and
immediately afterwards one inhalation of a green
diskus. None or one of the two devices contained an
active drug, according to the condition the patient
was allocated to. In the placebo condition, none of
the two devices contained an active drug. In the
formoterol condition, the turbohaler contained an
active drug (AstraZeneca, Oxiss 9 mg), while the
diskus did not. In the salmeterol condition the
diskus contained an active drug (GlaxoSmithKline,
Serevents 50 mg), while the turbohaler did not.
Active and placebo devices were visually identical.
Neither patients nor technicians knew the condi-
tion the patient was allocated to, as the researcher
took care of the randomization (alternate between
conditions). Symptoms (ASC and Borg-Score) and
pulmonary function (FEV1) were evaluated 5 and
20min after the technician administered an active
drug or placebo. Every patient received salbutamol
at the end of the study (GlaxoSmithKline, Vento-
lins 400 mg), to guarantee a maximal reversion of
the bronchusobstruction. Fifteen minutes after
salbutamol was administered, the fifth and last
measure moment took place. The local Ethical
Committee approved the study.Data analysis
The three conditions were compared on their
baseline clinical measures and on their socio-demographic measures, using chi-square (w2), one-
way ANOVA and Kruskal–Wallis as appropriate.
The main goal of our analyses consisted of
comparing the effects of salmeterol, formoterol
and placebo on symptoms experienced by the
patients and pulmonary function measures. These
analyses were based on the observed time
period going from measure moment 2–4. We
performed repeated measures analyses, using with-
in-subject difference scores: [measure moment
3—measure moment 2] and [measure moment
4—measure moment 2]. These values were used
in 2 (difference scores) 3 (conditions) repeated
measures ANCOVA’s with measure moment 1 and 2
as covariates. Measure moment 5 was kept out of
the analyses, as this measure was only used to
guarantee patient’s maximal reversion of the
bronchusobstruction.
To compare formoterol and salmeterol, means of
the difference scores [measure moment 3—mea-
sure moment 2] and [measure moment 4—measure
moment 2] were used for analyses. Unpaired t-tests
were performed to compare groups on the symptom
measures and the pulmonary function measures.
Computational analyses were performed with the
statistical program SPSS version 10.0.Results
Demographic and clinical characteristics at base-
line
Thirty subjects participated in the study (14
females, 16 males) with a mean age of 36 years
(range 19–58 years). The subjects’ characteristics
are described per condition in Table 1. The three
conditions significantly differed at baseline for Borg
Score (w2 ¼ 7:069, Po0:05). Only 23% of the
patients had earlier experience with long-acting
b2-agonists (20%, 20% and 30% in placebo-, for-
moterol- and salmeterol-condition, respectively).
Pulmonary function and symptom reporting in
the three conditions
The evolution of FEV1 and ASC from baseline to
measure moment 5 is represented in Figs. 1 and 2.
For convenience sake, values are expressed in % of
the baseline score.
Repeated measures analyses of covariance
showed a significant interaction effect between
measure moment and condition for FEV1 (F(2.25) ¼
5.571, P ¼ 0:010), indicating greater FEV1-changes
in formoterol and salmeterol condition compared
to placebo condition at measure moment 4. No
interaction or main effects were found for the
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Table 1 Demographic and clinical characteristics at baseline.
Condition
Placebo n ¼ 10 Formoterol n ¼ 10 Salmeterol n ¼ 10 P-value
Gender/sex (% males) 60 40 60
Age (years) 42 (10.9) 32.5 (9.6) 34 (9.6)
PC20 histamine (mg/ml) 3.6 3.4 3.5
FEV1 (% predicted) 101 (12.9) 94 (13.2) 105 (13.1)
ASC 31 (32.6) 37 (27.7) 27 (32.4)
Borg Score 1 (1.3) 4 (2.4) 2 (2.5) Kruskal–Wallis Po0.05
Medication prescribed (%)
Anti-histaminic 30 30 40
Inhaled steroids 30 20 40
Short-acting b2-agonists 10 20 0
Long-acting b2-agonists 20 20 30
Data are presented as mean (SD), unless otherwise stated.
PC20: provocative concentration of histamine used for a X20% fall in FEV1; FEV1: forced expiratory volume in 1 s; FVC: forced
vital capacity; ASC: Asthma Symptom Checklist Score.
Significant difference between groups at a Po0.05-level.
Figure 1 Mean FEV1 (% baseline) per condition from
measure moment 1–5. MM: measure moment. MM1:
baseline; MM2: after histamine provocation; MM3: 5min
after study drug and instructions; MM4: 20min after study
drug and instructions; MM5: 15min after salbutamol.
Figure 2 Mean ASC-score (% baseline) per condition from
measure moment 1–5. MM: measure moment. MM1:
baseline; MM2: after histamine provocation; MM3: 5min
after study drug and instructions; MM4: 20min after study
drug and instructions; MM5: 15min after salbutamol.
Long-acting bronchodilators and asthma symptoms 351different symptom measures, indicating similar
recovery of the asthma symptoms in the placebo
and active drug conditions.
Unpaired t-tests performed to compare the
effects of formoterol and salmeterol on the
symptom measures and pulmonary function did
not reveal any significant differences between
conditions, neither for the [measure moment
4—measure moment 2] nor for the [measure
moment 3—measure moment 2] difference scores.
The absolute mean changes in pulmonary func-
tion and symptom measures following bronchodi-
lator or placebo are shown in Table 2.Discussion
In the present study, we compared the effects of
salmeterol, formoterol and placebo on relief of
histamine-induced asthma symptoms and mild
bronchusobstruction.
Our data showed greater improvements of the
pulmonary function measures in the conditions in
which an active bronchodilator was administered
compared to a placebo condition. FEV1 showed
better improvement in the formoterol and salme-
terol condition than in the placebo condition 20min
after intake of the drug (Po0:05). We were
ARTICLE IN PRESS
Table 2 Absolute mean symptom and pulmonary function changes 5 and 20min following bronchodilator or
placebo.
Placebo n ¼ 10 Formoterol n ¼ 10 Salmeterol n ¼ 10
5min 20min 5min 20min 5min 20min
FEV1 (% predicted) 10 15 16 21 12 21
ASC total 33 50 40 51 29 40
Obstruction Scale 8 12 6 9 6 9
Dyspnea Scale 7 12 10 13 6 11
Fatigue Scale 8 10 8 10 5 6
Hyperventilation Scale 1 3 3 3 1 2
Anxiety Scale 2 2 4 5 2 3
Irritability Scale 2 4 4 6 3 3
Borg Score 2 4 3 4 2 4
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ASC: Asthma Symptom Checklist Score.
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FEV1 in the placebo condition after 5min. Different
reasons may account for this improvement. First, it
could be that the deep inspiration patients per-
formed when inhaling the drugs or placebo elicited
a bronchodilatory reaction in the patients’ airways.
Second, the instructions of bronchodilation might
have influenced the changes in FEV1. In a previous
study, Leigh et al.18 observed a significant fall in
FEV1 in suggestible asthmatics when saline was
suggested to be a bronchoconstrictor, although it is
not clear through which mechanisms this might
occur. Third, as we know that significant sponta-
neous improvements in FEV1 can occur within
10min after airway challenge, we think the
improvement could be due to natural recovery of
the bronchusobstruction. Even if the pulmonary
function technician was a trained technician and
the patients were quickly skilled in filling in the
questionnaires, we do realize that the time needed
for performing the measurements might have had a
slight impact on the exact time the measurements
took place. Therefore, measure moment 3 might
have varied around 5min after administration of
the study drugs or placebo, giving FEV1 more time
to improve spontaneously after the challenge. This
is, however, unavoidable in a study evaluating
symptom and pulmonary function relief after
bronchoconstriction.
No significant differences in mean improvement
were found in the observed time window (after 5
and 20min) among the formoterol and salmeterol
conditions, neither for the pulmonary function
measure nor for the symptom measures. In line
with the findings of Politiek et al.9 we expected
faster recovery of the pulmonary function in the
formoterol group than in the salmeterol group,
which should be noticeable 5min after the drug wasadministered. Although Fig. 1 shows a slight
tendency towards faster recovery for formoterol
after 5min, this was not significant. We have some
possible explanations for this finding. First, we
think that a more substantial difference may be
found with higher levels of bronchusobstruction: it
was mild (fall in FEV1X20%) in our study and severe
(fall in FEV1X30%) in the Politiek study. Second, it
might be related to the lower dose of formoterol
administered in our study. However, 9 mg of
formoterol was estimated to correspond to 50 mg
of salmeterol in a previous study and is known to be
the dose used in clinical practice.19 The fact that
the first measure of bronchodilator effect was only
performed 5min after the inhalation of the drugs,
could be another explanation for the lack of
difference between salmeterol and formoterol in
recovery of pulmonary function. The setup of our
study, however, did not allow performing earlier
measurements.
Unlike for the pulmonary function measures, no
differences among conditions were found for any of
the symptom measures. The patients’ symptoms in
the placebo condition recovered to the same
extent as those in the other two conditions, despite
less recovery in pulmonary function. The full
clinical relevancy of these remains uncertain, as
more studies are needed on this topic. In the
present study it is likely that the effects of the
instructions, suggesting bronchodilation prior to
taking drugs or placebo, did overrule the effects of
the drugs themselves. Indeed, previous studies
have shown important effects of suggestion of
bronchodilation and bronchusobstruction on symp-
tom reporting in asthmatics.20–23 Symptom percep-
tion in asthmatics has often been studied by
administering study drugs and by assessing pulmon-
ary function and symptoms in a parallel way. In
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indication of the instructions that were given to
the patients when administering the study drugs. It
is, however, important to pay attention to those
instructions, as they can be partly responsible for
the reported symptoms.
Although the study was performed with a limited
number of subjects therefore influencing the study
power, we believe that the mild bronchusobstruc-
tion provoked with histamine reproduces a real life
situation of a mild asthmatic attack well. The
applied dosages of the drugs were similar to those
used in clinical practice. In that perspective it is
relevant to conclude that after a histamine-
induced mild bronchusobstruction, a similar asthma
symptom recovery occurred when inhaling salme-
terol, formoterol or placebo, despite better recov-
ery of pulmonary function in the active drug
conditions.Acknowledgements
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